CAS: 5610-49-1; 1-Butylpiperazine

该化合物是一种有机化合物,其特征是其管子环,即六人环状环状结构,含有两个氮原子;该化合物的特征是,一个丁基体系附于管子环内氮原子,造成其疏水性能;它一般是一种无色的黄色黄色液体,具有一种独特的类似地雷的味道. 1-n-丁基-管道-管道-管道-在水和各种有机溶剂中溶解,使其具有多种用途,主要用于合成药物,农用化学品和有机化学的建筑块;它主要用于合成有机化学中的管道-管道-粘合剂,可以与生物系统进行可能的相互作用,可用于药物设计;此外,它可能表现出由于环状氮原子而具有的基本特性,从而可以作为质粒体的接受者.应当考虑到安全因素,因为接触时可能对健康造成危害,因此有必要进行适当的处理和储存.

结构式图片

相似化合物

412293-87-9 50866-75-6 4553-32-6

欧盟法规

ECHA物质C&L通报

上下游产品

CAS号110-85-0 哌嗪 | CAS号109-65-9 正溴丁烷 | CAS号2759-28-6 1-苄基哌嗪 | CAS号542-69-8 碘代正丁烷 | CAS号102-79-4 N-丁基二乙醇胺 | CAS号63981-41-9 4-Butyl-1-piper... | CAS号412293-87-9 1-B°C-4-丁基哌嗪 | CAS号21863-67-2 1-Piperazinecar... | CAS号7664-41-7 氨 | CAS号129791-91-9 3'-Hydroxy-5'-(...

合成工艺路线路线简述

    📜4-Butyl-Piperazine-1-Carboxylic Acid Tert-Butyl Ester置于三氟乙酸体系中,化学反应 16.0H,反应生成 1-丁基哌嗪
    参考文献:喹诺酮类抗生素对分枝杆菌的构效关系:在n-1和c-7处结构变化的影响.
    标题:喹诺酮类抗生素对分枝杆菌的构效关系:在n-1和c-7处结构变化的影响.
    摘要:对常规药物治疗有抵抗力的结核感染的再次出现表明需要针对结核分枝杆菌的替代化学疗法.作为优化针对结核分枝杆菌的喹诺酮类抗菌药物研究的一部分,我们准备了一系列n-1-和c-7取代的喹诺酮类化合物,以研究这两个位置上喹诺酮类修饰物与活性之间的特定结构-活性关系.对抗分枝杆菌.通过文献方法合成的化合物被评估了对福分枝杆菌和耻垢分枝杆菌以及革兰氏阴性和革兰氏阳性细菌的活性.化合物对堡垒分枝杆菌的活性用作结核分枝杆菌活性的晴雨表.
    DOI:10.1021/jm9507082

    海关参考信息

    专利信息


    专利号:US-6534627-B1
    优先权日:1989-10-23
    标题:Synthesis and use of amino acid fluorides as peptide coupling reagents
    发明人:CARPINO LOUIS A; EL-FAHAM AYMAN AHMED
    权利人:RES CORP TECHNOLOGIES INC
    摘要:The present invention is directed to the process of preparing a peptide comprising reacting a first amino acid or peptide with an amino acid fluoride of the formula: n or the acid fluoride salts thereof wherein n BLK is an N-amino protecting group; n AA is an amino acid residue; and n X is absent or a protecting group. n The amino acid fluoride is useful as a coupling agent in peptide synthesis.

    专利号:US-4678784-A
    优先权日:1984-04-11
    标题 :Method for the treatment of LHRH diseases and conditions
    发明人:HO CHIH Y
    权利人:MCNEILAB INC
    摘要:Fused tetracyclic benzodiazepines of the formula (I): (I) where R1 is a cyclic amine such as 1-piperazine and R2 is H or a substituent as defined herein are useful as LHRH antagonizing agents. Also, methods for their synthesis, intermediates used in such synthesis, methods for use as medicaments and pharmaceutical compositions are described.

    专利号:US-9670145-B2
    优先权日:2014-03-31
    标题:Process for preparing 1,1-disubstituted ethylene monomers
    发明人:TCHAPLINSKI VLADIMIR; GHERARDI STEFANO; DE LA FUENTE MOLINA VERÓNICA
    权利人:AFINITICA TECH S L
    摘要:The present invention relates to a process for preparing 1,1-disubstituted ethylene monomers having general formula (I) from a compound of general formula (II) and an active methylene compound of general formula (III) using a catalytic amount of an ammonium or iminium a salt in homogeneous phase or supported on a solid substrate. Said process allows the direct synthesis of the monomers and finds application in the preparation of a wide variety of monomers. The products obtained are reactive monomers of high purity which find application in the field of fast curing adhesives.

    专利号:WO-2006079916-A1
    优先权日:2005-01-26
    标 题 :Thieno [2,3-d] pyrimidine compounds as inhibitors of adp-mediated platelets aggregation
    发明人:ENNIS MICHAEL DALTON; KORTUM STEVEN WADE; RAHMAN HAYAT; SCHWEITZER BARBARA ANN; TENBRINK RUTH ELIZABETH
    权利人:PHARMACIA & UPJOHN CO LLC; ENNIS MICHAEL DALTON; KORTUM STEVEN WADE; RAHMAN HAYAT; SCHWEITZER BARBARA ANN; TENBRINK RUTH ELIZABETH
    摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I): wherein A1, A2, A3, A4, A5, A6, A7, A8, X4, X6, R2, R4, R5, and R6 are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

    专利号:US-2023357177-A1
    优先权日:2020-12-17
    标题:Synthesis of cannabidiol and analogs thereof, and related compounds, formulations, and methods of use

    专利号:US-4547497-A
    优先权日:1984-04-11
    标 题:Amidine benzodiazepines, methods for their use and intermediates
    发明人:HO CHIH Y
    权利人:MCNEILAB INC
    摘要:Fused tetracyclic benzodiazepines of the formula (I): ##STR1## where R 1 is an acyclic amine or cyclic amine such as 1-piperidine, 4-morpholine or 1-piperazine and R 2 is H or a substituent as defined herein as useful as antiallergins. Also, methods for their synthesis, intermediate used in such synthesis, methods for use as medicaments and pharmaceutical compositions.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    参考文献:10.1038/ncomms14193|10.1038/ncomms15273
    摘要:Pegoraro S, Duffey M, Otto TD, Wang Y, Rösemann R, Baumgartner R, Fehler SK, Lucantoni L, Avery VM, Moreno-Sabater A, Mazier D, Vial HJ, Strobl S, Sanchez CP, Lanzer M. Erratum: SC83288 is a clinical development candidate for the treatment of severe malaria. Nature Communications. 2017 Apr 06;8(1):15273. doi: 10.1038/ncomms15273.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知